These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 6130866)

  • 1. Nonlinear ethotoin kinetics.
    Meyer MC; Holcombe BJ; Burckart GJ; Raghow G; Yau MK
    Clin Pharmacol Ther; 1983 Mar; 33(3):329-34. PubMed ID: 6130866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent kinetics of ethotoin in man.
    Sjö ; Hvidberg EF; Larsen NE; Naestoft J
    Clin Exp Pharmacol Physiol; 1975; 2(3):185-92. PubMed ID: 238776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saturable metabolic pathways for ethotoin in man.
    Naestoft J; Hvidberg EF; Sjö O
    Clin Exp Pharmacol Physiol; 1976; 3(5):453-9. PubMed ID: 10117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of mephenytoin and ethotoin.
    Troupin AS; Friel P; Lovely MP; Wilensky AJ
    Ann Neurol; 1979 Nov; 6(5):410-4. PubMed ID: 42344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enantioselective pharmacokinetics of ethotoin in humans following single oral doses of the racemate.
    Hooper WD; O'Shea NJ; Qing MS
    Chirality; 1992; 4(3):142-7. PubMed ID: 1350205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethotoin in seizures of childhood and adolescence.
    Carter CA; Helms RA; Boehm R
    Neurology; 1984 Jun; 34(6):791-5. PubMed ID: 6145119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gas chromatographic-mass spectrometric studies on the metabolic fate of ethotoin in man.
    Bius DL; Yonekawa WD; Kupferberg HJ; Cantor F; Dudley KH
    Drug Metab Dispos; 1980; 8(4):223-9. PubMed ID: 6105055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass fragmentographic quantitation of ethotoin and some of its metabolites in human urine.
    Naestoft J; Larsen NE
    J Chromatogr; 1977 Mar; 143(2):161-9. PubMed ID: 14171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonlinear pharmacokinetics of ethanol: the disproportionate AUC-dose relationship.
    Wilkinson PK; Reynolds G; Holmes OD; Yang S; Wilkin LO
    Alcohol Clin Exp Res; 1980 Oct; 4(4):384-90. PubMed ID: 7004237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereoselective analysis of the enantiomers of ethotoin in human serum using chiral stationary phase liquid chromatography and gas chromatography-mass spectrometry.
    Inotsume N; Fujii J; Honda M; Nakano M; Higashi A; Matsuda I
    J Chromatogr; 1988 Jul; 428(2):402-7. PubMed ID: 2905704
    [No Abstract]   [Full Text] [Related]  

  • 12. Kinetics and metabolism of fomepizole in healthy humans.
    McMartin KE; Sebastian CS; Dies D; Jacobsen D
    Clin Toxicol (Phila); 2012 Jun; 50(5):375-83. PubMed ID: 22554311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial.
    Vollmer T; Henney HR
    Clin Ther; 2009 Oct; 31(10):2206-14. PubMed ID: 19922891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buffer catalysis of the racemization reaction of some 5-phenylhydantoins and its relation to the in vivo metabolism of ethotoin.
    Dudley KH; Bius DL
    Drug Metab Dispos; 1976; 4(4):340-8. PubMed ID: 8288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose dependent pharmacokinetics of theophylline: Michaelis-Menten parameters for its major metabolic pathways.
    Dadashzadeh S; Tajerzaden H
    Eur J Drug Metab Pharmacokinet; 2001; 26(1-2):77-83. PubMed ID: 11554438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphadenopathy induced by ethotoin (peganone); clinical and pathological mimicking of malignant lymphoma.
    SALTZSTEIN SL; JAUDON JC; LUSE SA; ACKERMAN LV
    J Am Med Assoc; 1958 Jul; 167(13):1618-20. PubMed ID: 13563153
    [No Abstract]   [Full Text] [Related]  

  • 17. Simultaneous rapid HPLC determination of anticonvulsant drugs in plasma and correlation with EMIT.
    Rydzewski RS; Gadsden RH; Phelps CA
    Ann Clin Lab Sci; 1980; 10(1):89-94. PubMed ID: 6987946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses.
    Nakashima M; Asano M; Ohguchi S; Hashimoto H; Seki T; Miyazaki M; Takenaka T
    Clin Pharmacol Ther; 1984 Oct; 36(4):436-43. PubMed ID: 6478731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacokinetic rationale for three times daily administration of ethotoin (Peganone).
    Browne TR; Szabo GK
    J Clin Pharmacol; 1989 Mar; 29(3):270-1. PubMed ID: 2566627
    [No Abstract]   [Full Text] [Related]  

  • 20. Single- and multiple-dose pharmacokinetics and tolerability of limaprost in healthy Chinese subjects.
    Chen H; Zhang Q; Li X; Zhang H; Sun Y; Yin L; Liu C; Cao Y; Gu J; Ding Y
    Clin Drug Investig; 2015 Mar; 35(3):151-7. PubMed ID: 25586152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.